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Abstract
Women with mutations in the breast cancer genes BRCA1 or BRCA2 have an increased lifetime risk of developing
breast, ovarian and other BRCA-associated cancers. However, the number of detected germline mutations in fami-
lies with hereditary breast and ovarian cancer (HBOC) syndrome is lower than expected based upon genetic linkage
data. Undetected deleterious mutations in the BRCA genes in some high-risk families are due to the presence of
intragenic rearrangements such as deletions, duplications or insertions that span whole exons. This article reviews
the molecular aspects of BRCA1 and BRCA2 rearrangements and their frequency among different populations. An
overview of the techniques used to screen for large rearrangements in BRCA1 and BRCA2 is also presented. The
detection of rearrangements in BRCA genes, especially BRCA1, offers a promising outlook for mutation screening in
clinical practice, particularly in HBOC families that test negative for a germline mutation assessed by traditional
methods.
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Introduction
The precise identification of germline BRCA1 and
BRCA2 mutations is a major concern for geneticists coun-
seling families with a high risk of breast and ovarian can-
cers. The most frequent mutations encountered in these
genes are deletions or insertions of a few bases or sin-
gle-base substitutions that result in premature stop codons
(Perrin-Vidoz et al., 2002; Narod and Foulkes, 2004). Such
point mutations occur throughout the coding sequence of
bothgenesandaccountfor10%-50%ofthegermlinemuta-
tions encountered in hereditary breast and ovarian cancer
(HBOC) families, depending on the inclusion criteria used
(Agata et al., 2005; Vasickova et al., 2007).
The observed frequencies of BRCA1 mutations are
lower than predicted by linkage analysis, with pathogenic
variationsinthecodingregionorsplicesitesofthegenebe-
ing found in approximately two-thirds of BRCA1-linked
families. This finding suggests that other dominant genes
(Ford et al., 1998; Armour et al., 2002) and/or low
penetrance alleles, such as the 1100delC mutation in
CHEK2, may be associated with the HBOC phenotype
(Puget et al., 1999; Nevanlinna and Barker, 2006). Indeed,
breast and ovarian cancers have been associated with
germline mutations in other genes that are involved in the
maintenance of genomic integrity, such as TP53, PTEN,
ATM, NBS1, RAD50, BRIP1 and PALB2. Inherited breast
cancer is currently considered a highly heterogeneous ge-
netic disease with respect to both the loci and alleles in-
volved (Walsh et al., 2006; Walsh and King, 2007).
Large genomic rearrangements have recently been
identified in HBOC families and account for a small but
still significant proportion of cases in several populations.
These mutations are usually pathogenic because deletions
or insertions of large genomic sequences within a coding
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Review Articleregion result in out-of-frame translation and usually lead to
a mutant peptide of abnormal structure and/or function
(Preisler-Adams et al., 2006). These mutations may be
overlookedbymostoftheavailablescreeninganddiagnos-
tic PCR-based methods that use qualitative rather than
quantitative methods and do not detect partial or complete
exon losses or gains (Armour et al., 2002). Large genomic
rearrangements of BRCA1 may account for up to one-third
of all disease-causing mutations in various populations,
while large genomic rearrangements in BRCA2 are less fre-
quently observed (Hansen et al., 2009).
Frequency of Large Rearrangements
As shown in Table 1, the frequency of large genomic
rearrangements varies considerably among populations.
Among HBOC families, the highest proportion of BRCA1
rearrangements has been observed in northern Italy, where
large genomic deletions account for approximately one-
third of the pathogenic BRCA1 mutations (Montagna et al.,
2003) and the overall prevalence of rearrangements in the
families studied is 23%. In the Netherlands, rearrange-
ments also represent a high proportion of all deleterious
mutations in BRCA1 (27%-36% of all germline mutations
in the gene) and are attributable to founder mutations
(Petrij-Bosch et al., 1997; Hogervorst et al., 2003). In con-
trast, western Danish families with HBOC have a BRCA1
rearrangement prevalence of 3.8% (Thomassen et al.,
2006). Another study done in Finland failed to detect any
rearrangements among 82 families with moderate or high
risk for HBOC (Lahti-Domenici et al., 2001). The latter
two studies indicate a lower frequency of genomic rear-
rangements in Nordic countries. Finally, a study in Canada
found no evidence of BRCA1 or BRCA2 genomic rear-
rangements in high-risk French-Canadian breast/ovarian
cancer families (Moisan et al., 2006).
This wide range in the prevalence of rearrangements
is most likely related to the different genetic backgrounds
of the populations studied, although the heterogeneity of
the clinical inclusion criteria used for HBOC in each study
may also have influenced the results. Furthermore, the
prevalence of rearrangements will be different in samples
that include only BRCA mutation-negative individuals by
sequencing compared to those that include previously un-
tested individuals at risk for HBOC. More recent studies
have encountered an intragenic rearrangement prevalence
of 6% and 12%, respectively, in high-risk patients in fami-
lies from the Czech Republic and the United States of
America who were negative for BRCA1/2 point mutations
by sequencing (Walsh et al., 2006; Vasickova et al., 2007).
In Germany, the prevalence of BRCA1 rearrangements is
lower, ranging from 1 in 59 (1.7%) to 1 in 17.5 (5.7%)
among high-risk families who are mutation-negative by se-
quencing (Hofmann et al., 2003; Hartmann et al., 2004;
Preisler-Adams et al., 2006).
Only a few studies have examined the prevalence of
BRCA2 rearrangements in larger sets of high-risk patients.
InareportfromAustralia,largegenomicrearrangementsin
BRCA2 were identified in 2% of 149 high-risk families that
tested negative for BRCA1 and BRCA2 point mutations
(Woodward et al., 2005). Agata et al. (2005) found a simi-
larfrequency(2.5%)ofBRCA2rearrangementsamong121
highly selected Italian families. In a recent study of Portu-
guese HBOC families, a single founder BRCA2 rearrange-
ment (c.156_157insAlu) was identified in 8% of the
familiesstudiedandisthemostfrequentBRCA2rearrange-
ment described to date (Machado et al., 2007).
Molecular Pathology of BRCA1
Rearrangements
Several BRCA1 germline rearrangements with well
characterized breakpoints have been reported (Mazoyer,
2005). These rearrangements are scattered throughout the
geneandalthoughmostofthemaredeletions,duplications,
triplications or combined deletion/insertion events have
also been described. The BRCA1 gene characteristically
has an extremely high density of intronic Alu repeats and a
duplicated promoter region containing a BRCA1 pseudo-
gene that most likely account for the occurrence of “hot
spots” that favor unequal homologous recombination
events(Smithetal.,1996;Pugetetal.,2002).Currently,45
different large genomic rearrangements have been charac-
terized worldwide, including deletions and duplications of
one or more exons (Table 1).
Alu sequences
Thehumangenomecontainsupto1millioncopiesof
interspersed Alu elements (approximately one Alu repeat
for every 5 kb) that apparently mediate chromosomal rear-
rangements and homologous recombination events, result-
ing in translocations, duplications, inversions or deletions
(Kolomietz et al., 2002; Tancredi et al., 2004). These se-
quencesarenamedAlubecausemostofthemembersofthis
family of repeats are cleaved by the bacterial restriction
endonuclease Alu I. Members of the Alu family show sig-
nificant homology but do not have identical sequences.
Around 500,000 members of the Alu family have been
identified and it is estimated that together they comprise
3% of the human genome. Approximately 41.5% of the
intronic sequences of BRCA1 consist of Alu elements (Fig-
ure 1) that range in size from 0.5 kb to 23.8 kb and are lo-
cated throughout the entire gene (Montagna et al., 1999).
Alu sequences have often been regarded as genomic
instability factors because they are responsible for recom-
binational “hot spots” in certain genes and are frequently
involved in exon shuffling during meiosis as a result of
non-homologous recombination. These sequences may
also act as regulatory factors in transcription, with struc-
tural roles (as “physical separators" of protein-protein
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.interactions during chromosome condensation in cellular
division) and functional roles (in alternative “splicing” or
as a connection between transcription factors) being pro-
posed.
The two most prevalent sub-classes of repetitive ele-
ments in the Alu family are LINEs (Long Interspersed Ele-
ments) and SINEs (Short Interspersed Elements). LINEs
span 6-8 kb and represent ~21% of the total human genome
DNA, whereas SINEs, which are derived from RNA poly-
merase transcripts, are shorter (100-300 bp) and represent
~13% of the human genome. LINEs and SINEs are mobile
elements that move via reverse transcription (Gad et al.,
2001).
The complete genomic sequence of BRCA1 was pub-
lished by Smith et al. (1996), who identified 138 individual
Alu elements within this gene. Rearrangements are less
common in the BRCA2 gene, probably because of a lower
frequencyofAlusequences(17%).Inmostofthewellchar-
acterizedrearrangementsdescribedintheliterature,thereis
good evidence for the involvement of Alu repeat elements
in the recombination event. For example, the BRCA1 exon
5-7 deletion described in German families results from a
non-allelic homologous recombination between AluSx in
intron 3 and AluSc in intron 7. Both Alu repeats share a ho-
mologous region of 15 bp at the crossover site. (Preisler-
Adams et al., 2006)
Non-functional pseudogenes
Another important cause of unequal recombination
within the coding region of certain genes is the presence of
non-functional pseudogenes with high sequence homology
toatleastpartsofthefunctionalgene.Pseudogenesareusu-
ally non-functional “relatives” of known genes that have
lost their protein-coding ability or are no longer expressed
in the cell (Vanin, 1985).
Puget et al. (2002) were the first to report this
mutationalmechanismfortheBRCA1gene.Intwofamilies
withHBOC,theseauthorsshowedthatthefirstexonsofthe
gene were replaced by those of the BRCA1 pseudogene,
BRCA1. This pseudogene had previously been shown to
lie ~30 kb upstream of BRCA1 (Barker et al., 1996; Brown
et al., 1996). The presence of a duplication containing most
of BRCA1 exons 1 and 2 and the identification of two dif-
ferentrecombinationeventsinvolvinghomologousregions
located in the BRCA1 gene and BRCA1, respectively, led
the authors to postulate that these regions were strong “hot
spots” for recombination. The mutant alleles identified in
440 Ewald et al.
Figure1-AluelementsinBRCA1(reproducedfromPavliceketal.2004,bypermissionofOxfordUniversityPress).Exonsaredepictedasredrectangles
and Alu sequences as arrows. Alu elements known to be involved in human exonic deletions and/or duplications are shown in blue.the study harbored a chimeric gene that consisted of
BRCA1 exons 1A, 1B, and 2 fused to BRCA1 exons 3-24.
This chimeric gene lacked both the BRCA1 promoter and
translation initiation codon and was therefore
non-functional (Hofmann et al., 2003).
Tandemly arranged short sequence repeats
Gross chromosomal deletions and/or insertions may
also be mediated by tandemly arranged short sequence re-
peats. Highly repetitive nonconding human DNA often oc-
curs in arrays (or blocks) of tandem repeats of sequences
which may be simple (1-10 nucleotides) or moderately
complex (tens to hundreds of nucleotides). Individual ar-
rays can occur at a few or many different chromosomal lo-
cations. Satellite DNA, which constitutes most of the
heterochromatic regions of the genome and is particularly
noticeable in the vicinity of centromeres, consists of very
large arrays of tandemly repeated DNA. Short repeats may
causeslippedmispairingduringreplication,resultinginde-
letions or duplications of varying sizes. Recombination in-
volving tandemly arranged short sequence repeats
underliesthe244bpdeletioninBRCA1exon5describedin
German HBOC families (Preisler-Adams et al., 2006).
BRCA2 Rearrangements
Onlyafewstudieshaveinvestigatedthepresenceand
frequencies of deleterious BRCA2 rearrangements, and
mostofthesewereeitherdoneonarelativelysmallnumber
of families or used cumbersome mutation detection meth-
ods of variable sensitivity (Agata et al., 2005).
Until recently, only two genomic rearrangements had
beenidentifiedinsixstudiesthatanalyzedhereditarybreast
cancerpatientsorprimarybreasttumorsamongdiverseEu-
ropean populations (Peelen et al., 2000; Lahti-Domenici et
al., 2001; Chin et al., 2001; Wang et al., 2001; Gad et al.,
2002; Bunyan et al., 2004). The greatly reduced incidence
oflargegenomicalterationsthataffectBRCA2comparedto
BRCA1mostlikelyreflectsdifferencesinthedensityofAlu
repeat sequences at the two loci, and these initial studies
were not very supportive of the inclusion of this type of
analysis in routine mutation testing of HBOC families
(Preisler-Adams et al., 2006).
To date, 16 BRCA2 germline rearrangements have
been reported. More recent studies have reported the fre-
quent occurrence of large genomic BRCA2 rearrangements
in male breast cancer families. Woodward et al. (2005) re-
ported three BRCA2 rearrangements in 25 families with at
leastonemalebreastcancer,butnoBRCA2rearrangements
in 114 families without male breast cancer, and Tournier et
al. (2004) described three BRCA2 rearrangements in 39
Frenchfamilieswithatleastonecaseofmalecancer.These
findings indicate that large genomic rearrangements in
BRCA2 are more frequent in families with male breast can-
cer.
Another recent study done in Portugal described a
common BRCA2 rearrangement involving an Alu element,
c.156_157insAlu in exon 3, in 17 (8%) of 210 HBOC fami-
lies (Machado et al., 2007).
Methods for Detecting Rearrangements
Classic methods for mutation detection (such as se-
quencing) are usually unable to identify large genomic re-
arrangements. Consequently, several alternative methods
have been developed for the analysis of structural genomic
abnormalities.Thesemethods,whicharedesignedtotarget
either one or a few specific loci, or to scan the whole ge-
nome, include Southern blotting, long-range PCR, fluores-
cent in situ hybridization (FISH), quantitative multiplex
PCRofshortfluorescentfragments(QMPSF),proteintrun-
cation test (PTT), comparative genomic hybridization
(CGH), real-time or quantitative PCR (RT-PCR or qPCR)
and multiplex ligation-dependent probe amplification
(MLPA). Although each of these methods has potential ad-
vantages and limitations, there have been very few large-
scale comparative analyses of these techniques. A brief
summary of the most common detection methods is pro-
vided below.
Southern blotting
Southern blotting is the transfer of DNA fragments
from an electrophoretic gel to a membrane support that re-
sults in immobilization of the fragments on the membrane
andinasemipermanentreproductionofthebandingpattern
of the gel. This technique can be used to detect changes in
copy number (deletions and duplications) when samples
are run in parallel (concomitantly) with an internal stan-
dard. In addition, large rearrangements may also be de-
tected by a size shift in the blotted DNA fragments.
Although frequently used in the past, this method has lost
popularityasaroutinediagnosticproceduresinceitislabo-
rious, time consuming, requires large amounts of high-
molecular weight DNA and its interpretation may be ham-
pered by false-negative results (Unger et al., 2000; Brown,
2001; De Lellis et al., 2007).
Long-range PCR
Long-range PCR uses a mixture of two thermostable
DNA polymerases (proofreading and non-proofreading),
thereby increasing the product size to 35 kb. The method
has been useful for identifying specific large aberrations,
including intragenic deletions, insertions, duplications and
chromosomal breakpoints in several disorders. Long-range
PCR was originally designed to detect changes in gene
copy number rather than translocations or inversions, re-
quires small amounts of DNA and is excellent for lo-
cus-specificidentificationofknownrearrangements.These
features make it ideal for diagnostic purposes. However,
thistechniqueislimitedbyitslowthroughputandisunable
to provide a genome-wide view of rearrangements, which
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genomic region delimited by the primers that are used
(Vasickova et al., 2007; Morozova and Marra, 2008).
Fluorescent in situ hybridization (FISH)
FISH is based on the hybridization of fluorescent
probes to metaphase or interphase nuclei followed by anal-
ysiswithafluorescencemicroscope.FISHcandetectvaria-
tions in copy number (deletions and duplications),
translocations and inversions. Copy number is assessed by
microscopic visualization. The most commonly used con-
ventional in situ hybridization protocol in cancer research
is dual-color FISH. This method involves labeling centro-
meres and the DNA region of interest with different colors
and estimating the probe copy number from the ratio of the
centromeric to noncentromeric signal. Dual-color FISH is
used to detect chromosomal gains or losses (aneuploidy),
intrachromosomal insertions, deletions, inversions, ampli-
fications and chromosomal translocations. The advantages
of FISH include the ability to analyze single cells, applica-
bility to a wide range of substrates, including fixed samples
(such as paraffin-embedded tissue), and relative simplicity
of use. The method cannot provide a genome-wide assess-
ment of DNA rearrangements, with the exception of gross
chromosomal aberrations detected by multifluor-based
techniques, and is thus of limited value for genome-wide
identification of smaller-scale chromosomal aberrations
(De Lellis et al., 2007; Morozova and Marra, 2008).
Quantitative multiplex PCR of short fluorescent
fragments (QMPSF)
QMPSF is a sensitive method for the detection of
genomic deletions or duplications based on the simulta-
neous amplification of short genomic fragments using
dye-labelled primers under quantitative conditions. The
PCR products are analyzed on a sequencing platform used
in the fragment analysis mode and the peak height and area
areproportionaltothequantityoftemplatepresentforeach
target sequence. In this setting, the height or area of peaks
corresponding to the loss of one allele will be half that of
normalsamples,whereasagainofoneallelewillresultina
50% increase. This method is rapid and sensitive and has
been used to screen for BRCA1 rearrangements (Casilli et
al., 2002; Bastard et al., 2007; Weitzel et al., 2007). How-
ever, it is not easily implemented in a routine mutation
analysis laboratory and requires a fair amount of previous
experience.
Protein truncation test (PTT)
The PTT method is a straightforward approach to
screen for biologically relevant gene mutations. The
method is based on the size analysis of products resulting
fromtranscriptionandtranslationinvitro.Proteinsoflower
mass than the expected full-length protein represent trans-
lation products derived from truncating frameshift or non-
sense mutations in the analyzed gene. Mutation detection
may be limited by the size and location of the rearrange-
ment in relation to the primers used in the assay. In addi-
tion, because of the low sensitivity of conventional PTT,
mutations can be detected only in samples that harbor a rel-
atively high number of mutated gene copies (Peelen et al.,
2000; Hauss and Müller, 2007).
Comparative genomic hybridization (CGH)
CGH(alsoknownaschromosomalmicroarrayanaly-
sis or CMA) is a molecular-cytogenetic method that has
been used to analyze variations in copy number (gains or
losses) of DNA from patients and/or tumor cells. The
method is based on the hybridization of fluorescently la-
beled tumor DNA and normal DNA to normal human
metaphase preparations. Using epifluorescence micros-
copy and quantitative image analysis, regional differences
in the fluorescence ratio of gains/losses vs. control DNA
canbedetectedandusedtoidentifyabnormalregionsinthe
genome. CGH does not identify structural chromosomal
aberrationssuchasbalancedreciprocaltranslocationsorin-
versions since they do not change the copy number.
AlthoughCGHisacomplextechniquethatrequiressignifi-
cant previous experience in cytogenetics and a specific
set-up in terms of infra-structure, it is an efficient method
for genome-wide screening of rearrangements (Rouleau et
al., 2007).
Real time polymerase chain reaction (qPCR)
Real time PCR, also known as quantitative real time
polymerase chain reaction (qPCR), is a polymerase chain
reaction-based technique used to amplify and simulta-
neously quantify a target DNA molecule. qPCR allows the
detection and quantification (as absolute number of copies
or relative amount when normalized to DNA input or addi-
tional normalizing genes) of a specific sequence in a DNA
sample. The procedure follows the general principle of
PCR, the key difference being that the amplified DNA is
quantifiedasitaccumulatesinthereactioninrealtimeafter
each amplification cycle. Two common methods of quanti-
fication are the use of fluorescent dyes that intercalate with
double-stranded DNA, and modified DNA oligonucleotide
probes that fluoresce when hybridized with a complemen-
tary DNA. Although this method is rapid and does not re-
quire a large amount of starting material, it has a limited
throughput. It is not suitable for the detection of trans-
locations or inversions or for genome-wide screening of re-
arrangements (Barrois et al., 2004; Morozova and Marra,
2008).
Multiplex ligation-dependent probe amplification
(MLPA)
MLPA is a multiplex PCR method developed to de-
tect abnormal copy numbers of different genomic DNA
sequences. Each MLPA probe consists of two oligonu-
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to a target sequence. All ligated probes have identical se-
quences at their 5’ and 3’ ends, permitting simultaneous
amplification in a PCR containing only one primer pair.
One of the two oligonucleotides of each MLPA probe has a
commonsequenceusedforPCRamplificationatthe5’end
and a target-specific sequence at the 3’ end. The 5’ region
of the second oligonucleotide of each probe is designed to
hybridise to the target sequence immediately adjacent to
the first oligonucleotide and its 3’ region has a common se-
quence used for PCR amplification and a “stuffer” se-
quence with different a specific length. Each probe gives
rise to an amplification product of unique size, due to the
variation in the stuffer sequence length. Because only li-
gated probes will be exponentially amplified during the
subsequent PCR reactions the number of probe ligation
products is a measure for the number of target sequences in
the sample. The amplification products of different sizes
are separated using capillary electrophoresis (Schouten et
al., 2002). Nevertheless, MLPA has certain drawbacks, in-
cluding false-negative scores when probes are designed
outside the region of interest, i.e., outside the region in-
volved in the rearrangement. MLPA is primarily used as a
screening tool to identify rearrangements, and the precise
location of the deletion or duplication breakpoints in the
usually very large intronic or affected flanking regions
must be refined by sequencing (Staaf et al., 2008). In addi-
tion, in rare cases, MLPA may give a false-positive result
for a deletion due to occurrence of a point mutation within
the sequence of MLPA probe hibridisation (Gomez et al.,
2009). However, compared to most other techniques,
MLPA is an inexpensive, sensitive, relatively simple, and
high-throughput method (Hogervorst et al., 2003; Dunnen
and White, 2006; Ratajska et al., 2008). The use of MLPA
has facilitated the screening of genomic rearrangements in
BRCA1 (Montagna et al., 2003; Hartmann et al., 2004) and
BRCA2 (Woodward et al., 2005).
Conclusion
Point mutations in the BRCA genes are the most com-
mon deleterious mutations encountered in HBOC families,
and full gene sequencing and other PCR-based methods re-
main the gold standard for initial mutation identification.
However, rearrangements in these genes have been de-
scribed in a significant proportion of HBOC families, and
are responsible for up to one-third of the identifiable BRCA
mutations in certain populations. Consequently, in HBOC
families that test negative for BRCA point mutations by
conventional approaches, screening for large gene rear-
rangements in BRCA1 and probably also BRCA2 should be
strongly considered. A suggested flowchart for investiga-
tioninthesefamiliesispresentedinFigure2.Theavailabil-
ity of relatively inexpensive and technically straightfor-
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Figure 2 - Suggested approach for molecular investigation of hereditary breast and ovarian cancer (HBOC) families. The mutation probabilities are esti-
matedbyusingstandardprotocolsand/orriskestimationtoolssuchasBRCAPro,BOADICEAandtheMyriadmutationprevalencetables.ASCO:Amer-
ican Society of Clinical Oncology.wardscreeningmethodshasgreatlysimplifiedthisprocess,
but often more than one method must be used to fully char-
acterize a deletion or duplication in a given patient. Several
studies in different populations have proven the usefulness
ofscreeningforBRCA1rearrangements,howevertheprev-
alence of such mutations in a given population should be
known before definitive recommendations are made re-
garding the routine testing for rearrangements. In popula-
tions where there are highly prevalent founder rearrange-
ments, preliminary screening for pathogenic BRCA gene
mutations may be a cost-effective initial strategy.
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